NCT01204112已完成1 期
A Phase 1, Open Label, Fixed-Sequence Study To Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- AUCinf of tasocitinib (CP-690,550)
研究概览
简要总结
The current study is designed to estimate the effect of rifampin (600 mg orally every 24 hours for 7 days) on pharmacokinetics of single 30 mg dose (CP-690,550) in normal healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and/or female subjects (of non-childbearing potential)
排除标准
- •Clinically significant disease or condition
- •Recent serious infection
研究组 & 干预措施
Tasocitinib (CP-690,550) plus Rifampin
Experimental
干预措施: Tasocitinib (CP-690,550) plus Rifampin (Drug)
结局指标
主要结局
AUCinf of tasocitinib (CP-690,550)
时间窗: 9 days
Cmax of tasocitinib (CP-690,550)
时间窗: 9 days
次要结局
- AUClast, Tmax, t1/2 of tasocitinib (CP-690,550)(9 days)
- Safety: clinical laboratory abnormalities, AE reporting, and vital signs (blood pressure/pulse rate).(9 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of CamlipixantCoughHealthyNCT05899829Bellus Health Inc. - a GSK company42
已完成
1 期
Effects of Rifampin on the Pharmacokinetics of AtalurenHealthyNCT02409004PTC Therapeutics15
已完成
1 期
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced CancerHematologic MalignancyMalignant LymphomaNCT01324323Celgene14
已完成
1 期
Study of VX-770 and Rifampin in Healthy Male SubjectsCystic FibrosisNCT01018368Vertex Pharmaceuticals Incorporated24
已完成
1 期
Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy VolunteersHealthyNCT01147055Pfizer15